These studies indicate that down regulation of drug transporters during co-treatment (UroA/UAS03 + 5FU) enable effective elimination of 5FUR cancer cells potentially through FOXO3-FOXM1 signaling leading to reduced tumor size. This evidence concerns the gene FOXO3 and cancer.